Spots Global Cancer Trial Database for blastic plasmacytoid dendritic cell neoplasm
Every month we try and update this database with for blastic plasmacytoid dendritic cell neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) | NCT02859623 | Blastic Plasmac... Hematological M... | - | Centre Hospitalier Universitaire de Besancon | ||
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | NCT06013423 | Acute Leukemia ... Acute Lymphobla... Acute Myeloid L... Blastic Plasmac... Hematopoietic a... Mixed Phenotype... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Chronic Myeloid... | Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Cyclosporine Diagnostic Imag... Echocardiograph... Fludarabine Pho... Multigated Acqu... Mycophenolate M... Survey Administ... Thiotepa Total-Body Irra... Umbilical Cord ... | 6 Months - 65 Years | Fred Hutchinson Cancer Center | |
| Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant | NCT04317781 | Blastic Plasmac... | Tagraxofusp-erz... | 2 Years - | M.D. Anderson Cancer Center | |
| Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant | NCT04317781 | Blastic Plasmac... | Tagraxofusp-erz... | 2 Years - | M.D. Anderson Cancer Center | |
| Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. | NCT04109482 | Blastic Plasmac... | MB-102 Fludarabine Cyclophosphamid... | 18 Years - | Mustang Bio | |
| An Open-label Phase II Study of Lorvotuzumab Mertansine | NCT02420873 | Leukemia | Lorvotuzumab Me... | 18 Years - | M.D. Anderson Cancer Center | |
| Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | NCT04216524 | Blastic Plasmac... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Mercaptopurine Methotrexate Methylprednisol... Prednisone Rituximab Tagraxofusp-erz... Venetoclax Vincristine | 18 Years - | M.D. Anderson Cancer Center | |
| SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | NCT03113643 | Acute Myeloid L... Myelodysplastic... Blastic Plasmac... | Azacitidine SL-401 Venetoclax | 18 Years - | Dana-Farber Cancer Institute | |
| Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant | NCT04317781 | Blastic Plasmac... | Tagraxofusp-erz... | 2 Years - | M.D. Anderson Cancer Center | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | NCT05362773 | Leukemia, Acute... Myelodysplastic... Classical Hodgk... Leukemia, B-cel... Leukemia, Hairy... Mastocytosis, A... Blastic Plasmac... Chronic Myeloid... | MGD024 | 18 Years - | MacroGenics | |
| DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | NCT00397579 | Leukemia Myelodysplastic... Blastic Plasmac... | DT388IL3 | 18 Years - | University of Texas Southwestern Medical Center | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | NCT02220985 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Allogeneic Hema... Blast Phase Chr... Blastic Plasmac... Childhood Acute... Childhood Acute... Donor Lymphoblastic L... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Acut... Refractory Acut... Acute Lymphobla... Acute Myeloid L... | Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Methotrexate Mycophenolate M... Peripheral Bloo... Peripheral Bloo... Tacrolimus Thiotepa Total-Body Irra... | - 60 Years | Fred Hutchinson Cancer Center | |
| Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | NCT03485547 | Blastic Plasmac... | Venetoclax | 18 Years - | Dana-Farber Cancer Institute | |
| Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant | NCT04317781 | Blastic Plasmac... | Tagraxofusp-erz... | 2 Years - | M.D. Anderson Cancer Center | |
| DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | NCT00397579 | Leukemia Myelodysplastic... Blastic Plasmac... | DT388IL3 | 18 Years - | University of Texas Southwestern Medical Center | |
| SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | NCT03113643 | Acute Myeloid L... Myelodysplastic... Blastic Plasmac... | Azacitidine SL-401 Venetoclax | 18 Years - | Dana-Farber Cancer Institute | |
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | NCT03386513 | Blastic Plasmac... Myeloproliferat... | IMGN632 | 18 Years - | ImmunoGen, Inc. | |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | NCT03404193 | Acute Myeloid L... Acute Myeloid L... Blastic Plasmac... Chronic Myelomo... Mixed Phenotype... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Blast... Recurrent Chron... Recurrent Mixed... Refractory Acut... Refractory Blas... Refractory Chro... Refractory Mixe... | Decitabine Laboratory Biom... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population. | NCT03974971 | Blastic Plasmac... | - | Samsung Medical Center | ||
| Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN | NCT03203369 | Blastic Plasmac... | UCART123 | 18 Years - 80 Years | Cellectis S.A. | |
| Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN | NCT03203369 | Blastic Plasmac... | UCART123 | 18 Years - 80 Years | Cellectis S.A. | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | NCT05362773 | Leukemia, Acute... Myelodysplastic... Classical Hodgk... Leukemia, B-cel... Leukemia, Hairy... Mastocytosis, A... Blastic Plasmac... Chronic Myeloid... | MGD024 | 18 Years - | MacroGenics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
